<DOC>
	<DOCNO>NCT02126943</DOCNO>
	<brief_summary>Prospective observational drug registry develop characterize safety profile ( include primarily potential serious hepatic risk ) describe clinical characteristic outcomes patient newly treat Opsumit post-marketing setting .</brief_summary>
	<brief_title>OPsumit USers Registry</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Macitentan</mesh_term>
	<criteria>Patients newly treat Opsumit define new user therapy , initiate â‰¤ 30 day prior enrollment visit . Signed ICF Previous user Opsumit define patient initiated therapy &gt; 30 day prior enrollment . Patients enrol ongoing clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>PAH</keyword>
	<keyword>pulmonary arterial hypertension</keyword>
</DOC>